Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2C0DY
|
|||
| Drug Name |
SPL-108
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [1] | |
| Ovarian epithelial cancer [ICD-11: 2C73; ICD-10: C56] | Phase 2 | [2] | ||
| Company |
Splash Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Extracellular matrix receptor III (CD44) | Target Info | Inhibitor | [1] |
| KEGG Pathway | ECM-receptor interaction | |||
| Hematopoietic cell lineage | ||||
| Shigellosis | ||||
| Epstein-Barr virus infection | ||||
| Proteoglycans in cancer | ||||
| MicroRNAs in cancer | ||||
| NetPath Pathway | IL5 Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| TNFalpha Signaling Pathway | ||||
| Panther Pathway | Alzheimer disease-presenilin pathway | |||
| Pathway Interaction Database | Osteopontin-mediated events | |||
| a4b7 Integrin signaling | ||||
| Reactome | Degradation of the extracellular matrix | |||
| Cell surface interactions at the vascular wall | ||||
| Integrin cell surface interactions | ||||
| Hyaluronan uptake and degradation | ||||
| Interferon gamma signaling | ||||
| WikiPathways | Senescence and Autophagy in Cancer | |||
| Wnt Signaling Pathway and Pluripotency | ||||
| Glycosaminoglycan metabolism | ||||
| Extracellular matrix organization | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Splash Pharmaceuticals. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.